Clinical Trials
3 trialsNCT00385827 2014-08-20
A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)
Centocor, Inc.
Phase 2 Terminated
NCT00311545 2013-02-20
S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT00433446 2013-02-05
S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
SWOG Cancer Research Network
Phase 2 Completed